secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001493152-24-010114
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics enters amended CEO agreement with $300K salary, transaction bonus provision
--------------------------------------------------------------------------------

- CEO Jeffrey Frelick receives $300,000 annual base salary, bonus target of 50% of salary, and transaction bonus of 1-2% of deal value upon acquisition.
- CFO Deina Walsh granted transaction bonus eligibility of 0.5-1% of deal value via amendment effective March 11, 2024.
- Frelick's agreement renews automatically; severance includes one year base salary plus COBRA coverage for one year if terminated without cause.
- Both agreements contain standard restrictive covenants and will be filed in the next quarterly report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315224010114/0001493152-24-010114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315224010114/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer